Published on
Monday, March 4, 2013
Piloting any biopharma company
through successive phases of growth and evolution can require changes in the
CEO's office as new challenges dictate the need for different kinds of
experience and skillsets. Likewise, as the industry navigates a future that
will be characterized by unprecedented commercial uncertainty, rapid
globalization and shrinking margins, continued growth will require a new breed
of CEO.
According Angus Russell, who is retiring as CEO of Shire plc,
the time has come for chief executives who can apply strategic thinking to
meeting the needs of increasingly diverse markets, and who understand those
markets in a way that is fundamentally different from the commercial CEOs of the
past.